Overview

Belimumab in Remission of VASculitis

Status:
Completed
Trial end date:
2017-02-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of belimumab, in combination with azathioprine, for the maintenance of remission following a standard induction regimen in patients with Wegener's granulomatosis or microscopic polyangiitis. The random assignment in this study is "1 to 1" which means that participants have an equal chance of receiving belimumab or placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Human Genome Sciences Inc., a GSK Company
Collaborator:
GlaxoSmithKline
Treatments:
Azathioprine
Belimumab